ProfileGDS5678 / 1415994_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 73% 85% 97% 95% 91% 95% 98% 98% 98% 84% 96% 95% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9628693
GSM967853U87-EV human glioblastoma xenograft - Control 24.7127873
GSM967854U87-EV human glioblastoma xenograft - Control 36.4239885
GSM967855U87-EV human glioblastoma xenograft - Control 49.4555897
GSM967856U87-EV human glioblastoma xenograft - Control 58.5889595
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.2149491
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.2876495
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.617798
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 410.21898
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 110.621198
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2152684
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.116896
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.4380995
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.4182695